JP2000507594A - 経口の生物学的利用率増大のための親油性化合物の固形脂質組成物 - Google Patents
経口の生物学的利用率増大のための親油性化合物の固形脂質組成物Info
- Publication number
- JP2000507594A JP2000507594A JP9535573A JP53557397A JP2000507594A JP 2000507594 A JP2000507594 A JP 2000507594A JP 9535573 A JP9535573 A JP 9535573A JP 53557397 A JP53557397 A JP 53557397A JP 2000507594 A JP2000507594 A JP 2000507594A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lipid
- solid
- dry
- coq10
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 哺乳類に投与した場合に治療作用をもたらすのに十分な量の親油性物質であ る第一成分;少なくとも1種の固形脂肪を含有する脂質である第二成分;及び 、少なくとも1種のリン脂質である第三成分を含有する、乾燥固形脂質組成物 であって、第二及び第三の成分が、哺乳類に投与した場合に該親油性物質の経 口の生物学的利用率を上昇するのに十分な量存在する、上記組成物。 2. 前記第一成分が、約0.01〜50重量%の量で存在し、第二成分が約20〜75重量 %の量、及び第三成分が約2〜40重量%の量で存在し、これらの3種の成分の 合計が、該組成物の100%である、請求の範囲第1項記載の組成物。 3. 更に凍結保護物質、抗酸化剤、易流動性付与剤、固形担体及び希釈剤からな る群から選択された薬剤を含む、請求の範囲第1項記載の組成物。 4. 前記脂質が、両方とも約25℃で固形であるような、トリグリセリド及びトリ グリセリド混合物からなる群から選択される、請求の範囲第1項記載の組成物 。 5. 前記脂質を、該組成物の総固形重量の約25〜75%含む、請求の範囲第1項記 載の組成物。 6. 前記リン脂質が、レシチンである、請求の範囲第1項記載の組成物。 7. 前記リン脂質の、総脂質に対する重量比が、約0.1:1から2:1である、請求の 範囲第1項記載の組成物。 8. 前記固形担体が、ヒュームド二酸化ケイ素を、該組成物の総固形重量の約5 〜50%の量含む、請求の範囲第3項記載の組成物。 9. 前記組成物が、単位投与剤形で存在する、請求の範囲第1項記載の組成物。 10.前記投与剤形が、ゼラチンカプセル剤、錠剤、及び該組成物の懸濁液を含有 する飲料からなる群から選択される、請求の範囲第9項記載の組成物。 11.前記親油性物質が、薬剤である、請求の範囲第1項記載の組成物。 12.前記親油性物質が、ビタミン及びホルモンからなる群から選択される、請求 の範囲第11項記載の組成物。 13.前記親油性物質が、ステロイド、ステロイド拮抗剤、非ステロイド系抗炎症 剤、抗真菌剤、抗菌剤、降圧剤、抗酸化剤、抗てんかん剤、抗ウイルス剤、抗 がん剤、又は抗鬱剤である、請求の範囲第1項記載の組成物。 14.前記親油性物質が、カンナビノイド又はビタミンである、請求の範囲第1項 記載の組成物。 15.下記の工程を含む、請求の範囲第1項記載の乾燥固形脂質組成物の製造法: 適当な有機溶媒中に、前述の3種の成分を溶解する工程;及び この分散液を乾燥し、脂質乾燥−薬剤混合物を生成する工程。 16.下記の工程を含む、請求の範囲第1項記載の乾燥固形脂質組成物の製造法: 適当な有機溶媒中に、前述の3種の成分を溶解する工程; この溶媒を蒸発し、完全に乾固する工程; こうして得られた乾燥固形脂質混合物を、水相で、水和し、水を溶媒とする脂 質分散液を得る工程; こうして得られた脂質分散液を、ホモジナイズして、粒度をサブミクロン値域 まで小さくする工程;及び このホモジナイズした分散液を乾燥し、脂質乾燥−薬剤混合物を生成する工程 。 17.前記乾燥が、該分散液の噴霧乾燥又は凍結乾燥によって達成される、請求の 範囲第15項記載の方法。 18.乾燥前に、前記分散液に、更に、凍結保護物質又は固形希釈剤を添加する工 程を含む、請求の範囲第15項記載の方法。 19.乾燥前に、更に、前記分散液に、合成界面活性剤又は乳化剤を添加し、液体 媒質中の該組成物の再懸濁を補助する工程を含む、請求の範囲第15項記載の方 法。 20.請求の範囲第1項記載の組成物の治療有効量を経口投与することを含む、こ のような物質が必要な哺乳類への親油性物質のデリバリー法。 21.前記組成物が、哺乳類の運動機能を向上するために投与される、請求の範囲 第20項記載の方法。 22.前記組成物が、歯周病、血行障害、記憶障害、疲労、免疫不全、不規則な心 拍動、心疾患、加齢、外来細胞毒が誘発した退化、又は脳損傷を患う哺乳類へ 投与される、請求の範囲第20項記載の方法。 23.前記心疾患が、心筋障害及び動脈硬化症からなる群から選択された、請求の 範囲第22項記載の方法。 24.前記親油性物質が、カンナビノイド又はビタミンである、請求の範囲第22項 記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL117773 | 1996-04-02 | ||
IL11777396A IL117773A (en) | 1996-04-02 | 1996-04-02 | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
PCT/US1997/005453 WO1997036577A1 (en) | 1996-04-02 | 1997-04-02 | Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000507594A true JP2000507594A (ja) | 2000-06-20 |
JP2000507594A5 JP2000507594A5 (ja) | 2004-12-09 |
JP4219403B2 JP4219403B2 (ja) | 2009-02-04 |
Family
ID=11068733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53557397A Expired - Fee Related JP4219403B2 (ja) | 1996-04-02 | 1997-04-02 | 経口の生物学的利用率増大のための親油性化合物の固形脂質組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5989583A (ja) |
EP (1) | EP0954284B1 (ja) |
JP (1) | JP4219403B2 (ja) |
AT (1) | ATE301454T1 (ja) |
AU (1) | AU722217B2 (ja) |
BR (1) | BR9708423A (ja) |
DE (1) | DE69733966T2 (ja) |
ES (1) | ES2249797T3 (ja) |
IL (1) | IL117773A (ja) |
WO (1) | WO1997036577A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004323444A (ja) * | 2003-04-25 | 2004-11-18 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 凍結乾燥微粒子製剤およびその製法 |
JP2005521710A (ja) * | 2002-04-03 | 2005-07-21 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 安定化された天然カンナビノイド調剤 |
JP2006206455A (ja) * | 2005-01-25 | 2006-08-10 | Univ Kinki | 薬物徐放出性微粒子及びその製造方法 |
JP2009502968A (ja) * | 2005-07-28 | 2009-01-29 | アイエスピー インヴェストメンツ インコーポレイテッド | 優れた生物学的利用能のベンゾキノン類 |
JP2011518549A (ja) * | 2008-04-08 | 2011-06-30 | ロケット・フルーレ | 高流動性および耐ケーキング性を有する粉末状結晶マルチトール組成物 |
JP2018516281A (ja) * | 2015-05-28 | 2018-06-21 | インシス・ディベロップメント・カンパニー・インコーポレイテッド | 安定なカンナビノイド製剤 |
JP2018516945A (ja) * | 2015-06-12 | 2018-06-28 | インデナ エッセ ピ ア | コエンザイムq10の固体分散体 |
JP2019508034A (ja) * | 2016-03-02 | 2019-03-28 | パスウェイ インターミディエーツ リミテッド | 特定の糖脂質を含む動物飼料 |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726343D0 (en) * | 1997-12-13 | 1998-02-11 | Auffret Anthony | The use of excipients to accelerate freeze-drying |
AU755445B2 (en) * | 1998-05-07 | 2002-12-12 | Corixa Corporation | Adjuvant composition and methods for its use |
US6200550B1 (en) * | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
PT1154759E (pt) | 1998-12-30 | 2008-11-20 | Dexcel Ltd | Concentrado dispersível para administração de ciclosporina |
US6242491B1 (en) * | 1999-06-25 | 2001-06-05 | Rima Kaddurah-Daouk | Use of creatine or creatine compounds for skin preservation |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
AU2001257359A1 (en) | 2000-04-27 | 2001-11-07 | Verion Inc. | Zero order release and temperature-controlled microcapsules and process for the preparation thereof |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
GB0014437D0 (en) * | 2000-06-14 | 2000-08-09 | Porter William L | Immune response stimulation |
WO2002002081A1 (en) * | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US6375982B1 (en) | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
DE10035513A1 (de) * | 2000-07-21 | 2002-01-31 | Beiersdorf Ag | Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen |
JP2004509739A (ja) | 2000-09-27 | 2004-04-02 | ベリオン インコーポレイテッド | 即時水溶解性カプセルおよびその製法 |
US6565873B1 (en) | 2000-10-25 | 2003-05-20 | Salvona Llc | Biodegradable bioadhesive controlled release system of nano-particles for oral care products |
US6589562B1 (en) | 2000-10-25 | 2003-07-08 | Salvona L.L.C. | Multicomponent biodegradable bioadhesive controlled release system for oral care products |
US6403116B1 (en) | 2000-11-03 | 2002-06-11 | Triarco Inductries, Inc. | Coenzyme Q10 formulation |
EP1349541B1 (en) * | 2000-12-14 | 2006-10-04 | F. Hoffman-la Roche AG | Self emulsifying lipid matrix (selm) |
CA2432319A1 (en) | 2000-12-21 | 2002-07-18 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US6607784B2 (en) * | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6806069B2 (en) | 2001-01-09 | 2004-10-19 | Pharmachem Laboratories, Inc. | Ubiquinone composition and methods related thereto |
US6864231B2 (en) * | 2001-01-09 | 2005-03-08 | Pharmachem Laboratories, Inc. | Glycoprotein matrix compositions and methods related thereto |
ATE253353T1 (de) * | 2001-04-12 | 2003-11-15 | Vesifact Ag | Coenzym q10 enthaltende mikroemulsion- prekonzentrate und mikroemulsionen |
WO2003000236A1 (en) | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particles with improved solubilization capacity |
US7125568B2 (en) * | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
JP2005504090A (ja) | 2001-09-26 | 2005-02-10 | バクスター・インターナショナル・インコーポレイテッド | 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製 |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
WO2003034302A1 (fr) * | 2001-10-15 | 2003-04-24 | Stark Co., Ltd. | Serveur de fourniture de contenu et systeme de fourniture de contenu dote d'un tel serveur |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
US7714006B1 (en) | 2001-12-03 | 2010-05-11 | King Pharmaceuticals Research & Development, Inc. | Methods of modifying the bioavailability of metaxalone |
TW200302054A (en) | 2002-01-18 | 2003-08-01 | Kaneka Corp | Ubiquinone-enriched foods |
SE0200475D0 (sv) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral farmaceutisk beredning |
AR039194A1 (es) | 2002-04-03 | 2005-02-09 | Solvay Pharm Bv | Formulacion de cannabinoides naturales estabilizados |
US20060093661A1 (en) * | 2002-05-07 | 2006-05-04 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
MXPA05000977A (es) * | 2002-08-12 | 2005-05-16 | Pfizer Prod Inc | Composiciones farmaceuticas de farmacos semiordenados y polimeros. |
EP1478401B1 (en) * | 2002-08-19 | 2009-09-09 | Art Jen Complexus Inc. | Compositions comprising dietary fat complexer and methods for their use |
US20040115226A1 (en) * | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
CA2414763A1 (en) * | 2002-12-19 | 2004-06-19 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Tocopherol concentrates and method for producing same |
US20130085146A1 (en) * | 2003-01-14 | 2013-04-04 | Rodney J.Y. Ho | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7438903B2 (en) * | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
US20050096365A1 (en) * | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
EP1711163A2 (en) * | 2004-02-05 | 2006-10-18 | Baxter International Inc. | Dispersions prepared by use of self-stabilizing agents |
PT1720610E (pt) * | 2004-02-17 | 2011-02-10 | Matuschka Greiffenclau Markus Graf V | Composição moderadora do metabolismo de álcool |
WO2005105040A2 (en) * | 2004-04-26 | 2005-11-10 | Micelle Products, Inc. | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
US7803366B2 (en) * | 2004-05-07 | 2010-09-28 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
WO2006063109A2 (en) | 2004-12-09 | 2006-06-15 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
WO2006110924A2 (en) * | 2005-04-14 | 2006-10-19 | Jarrow Formulas, Inc. | Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration |
US8252326B2 (en) * | 2005-06-01 | 2012-08-28 | Catalent Australia Pty Ltd. | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 |
EP1909762A2 (en) * | 2005-07-28 | 2008-04-16 | Isp Investments Inc. | Amorphous efavirenz and the production thereof |
CN101232822B (zh) | 2005-07-29 | 2012-11-14 | 蒂马基金会 | 用于减缓乙醇代谢和用于降低乙醇诱导的疾病风险的组合物 |
WO2007076454A1 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
ES2836184T3 (es) * | 2006-05-02 | 2021-06-24 | Univ Miami | Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas |
US20070264312A1 (en) * | 2006-05-12 | 2007-11-15 | Skaggs Crawford B | Rheologically Modified Edible Oils |
WO2007148798A1 (ja) | 2006-06-22 | 2007-12-27 | Kaneka Corporation | 還元型補酵素q10含有組成物およびその製造方法 |
CN101516333A (zh) * | 2006-08-04 | 2009-08-26 | 英西斯治疗学股份有限公司 | 水性屈大麻酚制剂 |
ES2370062T3 (es) * | 2006-09-15 | 2011-12-12 | Echo Pharmaceuticals B.V. | Granulado que contiene una sustancia farmacéuticamente activa y un emulsionante y método para su producción. |
CN101541299B (zh) | 2006-09-15 | 2013-04-17 | 艾可制药有限公司 | 供舌下、口含或口服施用的不溶于水的药物活性物质的剂量单位 |
US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
WO2008080037A2 (en) | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Carotenoids of enhanced bioavailability |
EP1952803A1 (en) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
US10189957B2 (en) * | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
US20100092560A1 (en) * | 2007-04-16 | 2010-04-15 | Kaneka Corporation | Reduced coenzyme q10-containing particulate composition and method for producing the same |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
JP2010535774A (ja) * | 2007-08-06 | 2010-11-25 | インシス セラピューティクス インコーポレイテッド | 経口カンナビノイド液体製剤および治療方法 |
US9861656B2 (en) * | 2007-08-08 | 2018-01-09 | Allergy Research Group, Llc | Phospholipid compositions and use thereof to enhance spermatozoa motility and viability |
US20100062040A1 (en) * | 2008-08-22 | 2010-03-11 | Ackley Donald E | Water soluble drugs and supplements |
GB0909154D0 (en) * | 2008-09-25 | 2009-07-08 | Nanomaterials Tech Pte Ltd | A process for making particles for delivery of drug nanoparticles |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
WO2010143199A1 (en) * | 2009-06-11 | 2010-12-16 | Suven Nishtaa Pharma Private Limited | Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs |
EP2480208A1 (en) | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
US11224659B2 (en) * | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) * | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
WO2012059936A1 (en) | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2012129072A1 (en) | 2011-03-18 | 2012-09-27 | Particle Dynamics International, Llc | Solid particulate compositions comprising coenzyme q10 |
US10421943B2 (en) * | 2011-08-11 | 2019-09-24 | Allergy Research Group, Llc | Phospholipid compositions and use thereof to enhance spermatozoa motility, viability and resistance to oxydative damage |
KR102237799B1 (ko) | 2012-11-14 | 2021-04-08 | 더블유.알. 그레이스 앤드 캄파니-콘. | 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물 |
DE102013004263A1 (de) * | 2013-03-13 | 2014-09-18 | Martin Lipsdorf | Schnell lösliche orale Darreichungsform und Methode zur Herstellung derselben |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
AU2016324349A1 (en) * | 2015-09-17 | 2018-02-15 | Pharmako Biotechnologies Pty Limited | Ubiquinone and ubiquinol compositions, and methods relating thereto |
RU2605616C1 (ru) * | 2015-11-27 | 2016-12-27 | Закрытое акционерное общество "Институт экспериментальной фармакологии" | Липосомальное средство на основе убихинола и способ его получения |
CA3007438A1 (en) | 2015-12-07 | 2017-06-15 | Elka Touitou | Compositions of therapeutic substances, methods and uses thereof |
CA3176596A1 (en) * | 2015-12-09 | 2017-06-15 | Poviva Corp. | Methods for formulating orally ingestible compositions comprising lipophilic active agents |
US11166912B2 (en) * | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
US20220079881A1 (en) * | 2016-03-03 | 2022-03-17 | Ctt Pharma Inc. | Orally Administrable Composition |
BE1024442B1 (nl) * | 2016-07-27 | 2018-02-28 | Nutrisan Nv | Samenstelling en gebruik van een voedingssupplement |
US20190183815A1 (en) * | 2016-08-15 | 2019-06-20 | Corr-Jensen Inc. | TIME RELEASE OF CoQ10 |
EP3544614A4 (en) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | ORAL TESTOSTERONE UNDECANOATE THERAPY |
CA3063916A1 (en) | 2017-05-17 | 2018-11-22 | Berg Llc | Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa |
KR20200024940A (ko) | 2017-07-27 | 2020-03-09 | 로커스 아이피 컴퍼니 엘엘씨 | 의약품, 보충제 및 섭취된 물질의 생체 이용률을 향상시키기 위한 조성물 |
JP2021530431A (ja) * | 2018-04-16 | 2021-11-11 | ポビバ コーポレーションPoviva Corp. | ニコチン化合物を含ませた組成物及び其れ等の使用の方法 |
CN108379236B (zh) * | 2018-04-20 | 2020-02-18 | 武汉百纳礼康生物制药有限公司 | 一种非那雄胺缓释片及其制备方法 |
KR20210114409A (ko) | 2018-12-11 | 2021-09-23 | 디스럽션 랩스 인코퍼레이티드 | 치료제 전달용 조성물과 이의 이용 및 제조 방법 |
US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
US20220257772A1 (en) * | 2019-07-19 | 2022-08-18 | Spi Pharma, Inc. | Preparation of lipophilic active ingredients |
WO2021030250A1 (en) * | 2019-08-10 | 2021-02-18 | Locus Ip Company, Llc | Methods for increasing the bioavailability of otc and pharmaceutical drugs |
EP4013429A4 (en) * | 2019-08-14 | 2023-08-16 | Locus IP Company, LLC | DRINKABLE SUPPLEMENT COMPOSITION FOR IMPROVED HEALTH AND HYDRATING |
US11311559B2 (en) | 2020-04-20 | 2022-04-26 | Poviva Corp. | Compositions and methods for enhanced delivery of antiviral agents |
EP3919046A1 (en) | 2020-06-02 | 2021-12-08 | Athenion AG | Method for solubilizing natural, endogenous and synthetic cannabinoids |
US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55153713A (en) * | 1979-05-02 | 1980-11-29 | Kureha Chem Ind Co Ltd | Pharmaceutical preparation of ribosome containing active substance |
IT8219012A0 (it) * | 1982-01-06 | 1982-01-06 | Ausonia Farma Srl | Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche. |
US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
IT1191608B (it) * | 1985-02-01 | 1988-03-23 | Zambon Spa | Composizione farmaceutica e forme farmaceutiche che la contengono |
DE3919982A1 (de) * | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
US5179122A (en) * | 1991-02-11 | 1993-01-12 | Eastman Kodak Company | Nutritional supplement containing vitamin e |
US5480865A (en) * | 1994-02-25 | 1996-01-02 | Parkinson's Charitable Trust | Nutritional composition |
-
1996
- 1996-04-02 IL IL11777396A patent/IL117773A/xx not_active IP Right Cessation
-
1997
- 1997-04-02 WO PCT/US1997/005453 patent/WO1997036577A1/en active IP Right Grant
- 1997-04-02 BR BR9708423-9A patent/BR9708423A/pt unknown
- 1997-04-02 ES ES97920049T patent/ES2249797T3/es not_active Expired - Lifetime
- 1997-04-02 EP EP97920049A patent/EP0954284B1/en not_active Expired - Lifetime
- 1997-04-02 AT AT97920049T patent/ATE301454T1/de not_active IP Right Cessation
- 1997-04-02 JP JP53557397A patent/JP4219403B2/ja not_active Expired - Fee Related
- 1997-04-02 US US08/833,075 patent/US5989583A/en not_active Expired - Lifetime
- 1997-04-02 AU AU24339/97A patent/AU722217B2/en not_active Ceased
- 1997-04-02 DE DE69733966T patent/DE69733966T2/de not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005521710A (ja) * | 2002-04-03 | 2005-07-21 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | 安定化された天然カンナビノイド調剤 |
JP2004323444A (ja) * | 2003-04-25 | 2004-11-18 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 凍結乾燥微粒子製剤およびその製法 |
JP2006206455A (ja) * | 2005-01-25 | 2006-08-10 | Univ Kinki | 薬物徐放出性微粒子及びその製造方法 |
JP2009502968A (ja) * | 2005-07-28 | 2009-01-29 | アイエスピー インヴェストメンツ インコーポレイテッド | 優れた生物学的利用能のベンゾキノン類 |
JP2011518549A (ja) * | 2008-04-08 | 2011-06-30 | ロケット・フルーレ | 高流動性および耐ケーキング性を有する粉末状結晶マルチトール組成物 |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
JP2018516281A (ja) * | 2015-05-28 | 2018-06-21 | インシス・ディベロップメント・カンパニー・インコーポレイテッド | 安定なカンナビノイド製剤 |
JP2018516945A (ja) * | 2015-06-12 | 2018-06-28 | インデナ エッセ ピ ア | コエンザイムq10の固体分散体 |
US10905657B2 (en) | 2015-06-12 | 2021-02-02 | Indena S.P.A. | Solid dispersions of Coenzyme Q10 |
JP2019508034A (ja) * | 2016-03-02 | 2019-03-28 | パスウェイ インターミディエーツ リミテッド | 特定の糖脂質を含む動物飼料 |
JP7102343B2 (ja) | 2016-03-02 | 2022-07-19 | パスウェイ インターミディエーツ リミテッド | 特定の糖脂質を含む動物飼料 |
Also Published As
Publication number | Publication date |
---|---|
DE69733966D1 (de) | 2005-09-15 |
IL117773A0 (en) | 1996-08-04 |
JP4219403B2 (ja) | 2009-02-04 |
BR9708423A (pt) | 2000-01-04 |
ATE301454T1 (de) | 2005-08-15 |
US5989583A (en) | 1999-11-23 |
AU722217B2 (en) | 2000-07-27 |
AU2433997A (en) | 1997-10-22 |
EP0954284B1 (en) | 2005-08-10 |
IL117773A (en) | 2000-10-31 |
ES2249797T3 (es) | 2006-04-01 |
EP0954284A1 (en) | 1999-11-10 |
EP0954284A4 (en) | 2000-01-26 |
WO1997036577A1 (en) | 1997-10-09 |
DE69733966T2 (de) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4219403B2 (ja) | 経口の生物学的利用率増大のための親油性化合物の固形脂質組成物 | |
US5891469A (en) | Solid Coprecipitates for enhanced bioavailability of lipophilic substances | |
AU730216B2 (en) | Solid coprecipitates for enhanced bioavailability of lipophilic substances | |
JP3903061B2 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
US20050244488A1 (en) | Methods and formulations for enhansing the absorption and gastro-intestinal bioavailability of hydrophobic drugs | |
JPH0534334B2 (ja) | ||
US6416793B1 (en) | Formulations and use of controlled-release indole alkaloids | |
US20170216224A1 (en) | Solid particulate compositions comprising coenzyme q10 | |
US20120225118A1 (en) | Compositions for delivery of insoluble agents | |
EP1420767A1 (en) | Compositions containing itraconazole and their preparation methods | |
KR20180070667A (ko) | 주입액 또는 주사액으로서 및 주입용 농축액의 정맥내 투여를 위한 개선된 레보시멘단 제형 | |
EP3033110A1 (fr) | Nouveau systeme solide instantane auto-emulsionnant a base de cyclodextrines et d'huile (s) pour l'administration orale | |
JP2004521941A (ja) | 水分散性ステロール類含有自由流動粉体の製造方法 | |
JP2004513077A (ja) | 血管保護作用及び抗酸化作用を有する製剤及びその使用 | |
CA2251194C (en) | Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability | |
EP3854384A1 (en) | Pharmaceutical formulation comprising abiraterone acetate | |
NL2020916B1 (en) | Composition comprising dehydrated liposomes with nutritional supplement | |
IL126384A (en) | Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability | |
IL119176A (en) | Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances | |
MXPA99001663A (en) | Method for producing dispersible sterol formulations in a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040401 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071211 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080311 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080902 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081021 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081112 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |